Search

Displaying results 1411 - 1420 of 6076 in total
  1. Drug

    Lumateperone

    go.drugbank.com/drugs/DB06077
    ApprovedInvestigational

    [A189093] Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the treatment of schizophrenia. … [A189093,A189174] The data so far indicates that lumateperone can alleviate both positive and negative symptoms of schizophrenia.

  2. Drug

    Trifarotene

    go.drugbank.com/drugs/DB12808
    ApprovedInvestigational

    Trifarotene is a topical retinoid cream used in the treatment of acne vulgaris that was first approved for use in the United States in October 2019.

    Categories: Anti-Acne Preparations for Topical Use, Retinoids for Topical Use in Acne
  3. Drug

    Acrivastine

    go.drugbank.com/drugs/DB09488
    Approved

    Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever.

    Categories: Antihistamines for Systemic Use
  4. Drug

    Colestipol

    go.drugbank.com/drugs/DB00375
    Approved

    [FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia … absorption and enhanced secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not be good candidates for

    Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  5. Drug

    Zolmitriptan

    go.drugbank.com/drugs/DB00315
    ApprovedInvestigational

    [A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997. … [A193791] Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent the current "gold standard" for acute migraine treatment.

  6. Drug

    Latanoprostene bunod

    go.drugbank.com/drugs/DB11660
    Approved

    As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle glaucoma … The novelty of this agent subsequently lies in the proposed dual mechanism of action that stems from both its prostaglandin F2-alpha analog latanoprost acid metabolite and its ability to donate NO for

  7. Drug

    Naldemedine

    go.drugbank.com/drugs/DB11691
    ApprovedInvestigational

    Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation.

    Categories: Drugs for Constipation
  8. Drug

    Sunitinib

    go.drugbank.com/drugs/DB01268
    ApprovedInvestigational

    For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. … On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).

  9. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor], a CFTR potentiator, for

  10. Drug

    Amlexanox

    go.drugbank.com/drugs/DB01025
    ApprovedWithdrawn

    Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis.

    Categories: Drugs for Obstructive Airway Diseases